Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 242

The DOI matches its Crossref record.

A pilot study of the Histone‐Deacetylase inhibitor Givinostat in patients with JAK2V617F positive chronic myeloproliferative neoplasms

Open access
Rambaldi, Alessandro, Dellacasa, Chiara Maria, Finazzi, Guido, Carobbio, Alessandra, Ferrari, Maria Luisa, Guglielmelli, Paola, Gattoni, Elisabetta, Salmoiraghi, Silvia, Finazzi, Maria Chiara, Di Tollo, Silvia, D’Urzo, Carmine, Vannucchi, Alessandro M., Barosi, Giovanni, Barbui, Tiziano · 2010 · British Journal of Haematology

Abstract

Summary: A phase II A study was conducted to evaluate the safety and efficacy of Givinostat, a novel Histone‐Deacetylases inhibitor, in patients with Polycythaemia Vera (PV, n = 12), Essential Thrombocythaemia (ET, n = 1) and Myelofibrosis (n = 16), bearing the JAK2V617F mutation. The study was approved by the local ethics committees and all human participants gave written informed consent. Givinostat was given orally for 24 weeks at a starting dose of 50 mg twice daily. The median treatment duration was 20 weeks. Reasons for treatment discontinuation were disease progression (n = 6), grade 2 thrombocytopenia (n = 1), psychiatric symptoms (n = 1) and withdrawn consent (n = 2). A dose reduction was applied in 10 patients while a temporary interruption occurred in 15. Among 13 PV/ET patients, 1 complete, 6 partial and 4 no responses were documented at study end while 2 patients went off‐study, prematurely. Three major responses were registered among 16 MF patients. Pruritus disappeared in most patients and reduction of splenomegaly was observed in 75% of PV/ET and 38% of MF patients. Reverse transcription polymerase chain reaction identified a trend to reduction of the JAK2 V617F allele burden. Givinostat was well tolerated and could induce haematological response in most PV and some MF patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1365-2141.2010.08266.x

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 242

Metadata

Authors
Rambaldi, A., Dellacasa, C. M., Finazzi, G., Carobbio, A., Ferrari, M. L., Guglielmelli, P., Gattoni, E., Salmoiraghi, S., Finazzi, M. C., Di Tollo, S., D’Urzo, C., Vannucchi, A. M., Barosi, G., & Barbui, T.
Venue
British Journal of Haematology
Publisher
Wiley
Published
2010-08
Volume
150
Issue
4
Pages
446-455
ISSN
  • 0007-1048 (ISSN-L)
  • 1365-2141
OpenAlex
W1754059962
Cited by
242
References
0
FWCI
11.92
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A pilot study of the Histone‐Deacetylase inhibitor Givinostat in patients with JAK2V617F positive chronic myeloproliferative neoplasms. https://app.cochat.ai/papers/10.1111/j.1365-2141.2010.08266.x
The paper
Rambaldi, A., Dellacasa, C. M., Finazzi, G., Carobbio, A., Ferrari, M. L., Guglielmelli, P., Gattoni, E., Salmoiraghi, S., Finazzi, M. C., Di Tollo, S., D’Urzo, C., Vannucchi, A. M., Barosi, G., & Barbui, T. (2010). A pilot study of the Histone‐Deacetylase inhibitor Givinostat in patients with JAK2V617F positive chronic myeloproliferative neoplasms. British Journal of Haematology. https://doi.org/10.1111/j.1365-2141.2010.08266.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.